Advaxis awarded orphan drug designation for ADXS-HPV for treating invasive cervical cancer.
M2 PHARMA-May 2, 2014-Advaxis awarded orphan drug designation for ADXS-HPV for treating invasive cervical cancer
(C)2014 M2 COMMUNICATIONS
Cancer immunotherapies company Advaxis (NasdaqCM:ADXS) revealed on Thursday the receipt of orphan drug designation from the US Food and Drug Administration (FDA) for ADXS-HPV for the treatment of Stage II-IV invasive cervical cancer.
This Orphan Drug Designation was granted by the US Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD).
The company added that ADXS-HPV is an immunotherapy that is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into dysplastic and malignant tissues. Eliminating these cells can eliminate the dysplasia or malignancy.
ADXS-HPV is designed to infect antigen-presenting cells and direct them to generate a powerful, cellular immune response to HPV E7, concluded the company.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||May 2, 2014|
|Previous Article:||Alcobra wins second US patent for Metadoxine for cognitive disorders.|
|Next Article:||Miraculins advances talks over Scout DS distribution in China.|